Parent page: Personalized Treatment Plan
Cognitive reserve (CR) describes the brain's capacity to maintain function despite accumulating neuropathology. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), cognitive reserve takes on unique significance because these 4R-tauopathies attack cortical and subcortical circuits simultaneously, producing distinctive combinations of motor impairment alongside executive dysfunction, behavioral changes, and language deterioration. Higher cognitive reserve correlates with delayed clinical onset despite equivalent pathological burden.
In CBS/PSP, psychosocial interventions are essential because:
The brain's cognitive reserve can be enhanced through multiple pathways:
Neural Compensation Mechanisms:
Evidence-Based CR Interventions:
| Intervention | CBS Adaptation | PSP Adaptation | Evidence Level |
|---|---|---|---|
| Cognitive Stimulation | Verbal-dominant activities (word games, storytelling) | Audio-based materials (audiobooks, podcasts) | Moderate |
| Music Therapy | Unilateral percussion with less-affected hand | Rhythmic auditory stimulation for gait | Strong |
| VR/Immersive Technology | Balance training, gait cueing, ADL simulation | Seated VR, cognitive training, tele-VR | Moderate |
| Art Therapy | Abstract/expressive with less-affected hand | Large-format, tactile media | Moderate |
CurePSP Support Groups: Disease-specific peer support provides understanding that generic dementia groups cannot. Virtual options accommodate mobility limitations.
Caregiver–Patient Dyad Activities:
Technology-Facilitated Connection:
Purposeful Activity Preservation:
Caregivers are essential enablers of cognitive reserve interventions. Training should include:
Depression is common in CBS/PSP (40-60% prevalence). Key interventions:
| Treatment | Mechanism | CBS/PSP Considerations | Evidence |
|---|---|---|---|
| SSRIs (sertraline, citalopram) | Serotonin reuptake inhibition | First-line for depression | Moderate |
| Bupropion | Dopamine/norepinephrine | May help apathy | Limited |
| Methylphenidate | Dopamine stimulation | For severe apathy | Case reports |
| ECT | Neurotransmitter modulation | For severe, refractory cases | Case reports |
Anxiety affects 30-50% of CBS/PSP patients:
Frontal disinhibition and impulse control issues:
| Day | Morning (30 min) | Afternoon (30 min) |
|---|---|---|
| Mon | Music therapy | Cognitive stimulation (verbal games) |
| Tue | Physical exercise (stage-adapted) | Social engagement (support group) |
| Wed | SLP session (voice + narrative) | Art appreciation / creative activity |
| Thu | Physical exercise (dual-task) | Counseling/mental health check-in |
| Fri | Cognitive stimulation (executive tasks) | Caregiver-led activities, family engagement |
| Sat-Sun | Rest, family engagement | Optional light activity |
| Psychosocial Intervention | Interaction with Levodopa | Interaction with Rasagiline |
|---|---|---|
| Exercise (high-intensity) | May enhance motor benefit | Monitor for hypotension |
| Music therapy | No significant interaction | No significant interaction |
| Cognitive stimulation | No significant interaction | No significant interaction |
| SSRIs (depression) | May enhance orexin function | Caution: Serotonin syndrome risk with MAO-B |
| Buspirone | No significant interaction | No significant interaction |
| Clonazepam | CNS depression additive | CNS depression additive |
| Methylphenidate | May reduce levodopa efficacy | Avoid: Hypertension risk |
Critical: SSRIs (sertraline, fluoxetine, paroxetine) combined with rasagiline carry risk of serotonin syndrome. Use with extreme caution or avoid.
| Dimension | Score (0-10) | Rationale |
|---|---|---|
| Mechanistic Clarity | 8 | Strong conceptual rationale linking reserve, network compensation, and frontal vulnerability |
| Clinical Evidence | 5 | Clinical signals from dementia/atypical parkinsonism cohorts; no large CBS/PSP-specific RCTs |
| Preclinical Evidence | 4 | Animal support for exercise/enrichment; limited CBS/PSP-specific modeling |
| Replication | 5 | Effects replicated across neurodegenerative populations; limited CBS/PSP data |
| Effect Size | 4 | Modest effects dependent on adherence and caregiver support |
| Safety/Tolerability | 8 | Non-pharmacologic interventions generally safe when fall risk/dysphagia managed |
| Biological Plausibility | 8 | Convergent plausibility from network neuroscience and neuroplasticity data |
| Actionability | 9 | Highly implementable in home, clinic, and telehealth settings |
Total: 51/80 (64%)
Based on this patient's profile (male, 50 years, CBS/PSP differential, on levodopa + rasagiline):
Immediate actions:
Short-term (1-3 months):
Long-term: